Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.36 USD | +2.63% | +9.07% | -2.74% |
05-10 | HC Wainwright Adjusts Catalyst Pharmaceuticals' Price Target to $26 From $24, Keeps Buy Rating | MT |
05-09 | Transcript : Catalyst Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.74% | 1.88B | |
-2.35% | 89.08B | |
+3.55% | 40.9B | |
-13.84% | 32.25B | |
+54.18% | 25.14B | |
-15.81% | 15.39B | |
-6.49% | 11.91B | |
-41.29% | 11.89B | |
-11.75% | 11.64B | |
+6.52% | 9.03B |
- Stock Market
- Equities
- CPRX Stock
- News Catalyst Pharmaceuticals, Inc.
- Cantor Fitzgerald Raises Catalyst Pharmaceuticals' Price Target to $18 From $15, Maintains Overweight Rating